Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition

Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematopoietic malignancy, necessitating the exploration of innovative therapeutic approaches. Targeting epigenetic mechanisms has emerged as a promising avenue for cancer treatment. EP300 belongs to the KAT3 family of histone...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanan Jiang, Donghui Xing, Xiang He, Wenqi Wu, Hong Xu, Huimeng Sun, Yixin Zhai, Kaiping Luo, Zhigang Zhao
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
DLBCL
EP300
Epigenetics
A485
Histone acetyltransferases
Online Access:https://doi.org/10.1186/s12885-025-14257-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14257-y

Similar Items